Improved Cognitive-cerebral Function In Older Adults With Chromium Supplementation

この研究の注釈:

In older adults with evidence of memory decline, 1,000mcg chromium (as picolinate) daily for 12 weeks failed to influence glucose metabolism and did not influence depressive symptoms. Despite no influence on memory over the 12 weeks, there appeared to be significantly less inclusion errors during testing and increased activity in some regions of the right half of the brain during memory testing.


A 2-year, Open-label Pilot Study Of Adjunctive Chromium In Patients With Treatment-resistant Rapid-cycling Bipolar Disorder

この研究の注釈:

In patients with bipolar disorder given between 600-800mcg chromium daily, it seemed that a minority of persons reported less depressive symptoms after three weeks (30% response as assessed by HAMD, 39% as assessed by MADRS) with no apparent benefit reported for manic symptoms nor any longer term benefits being reported due to dropouts.

No placebo control used in this study.


Chromium Potentiation Of Antidepressant Pharmacotherapy For Dysthymic Disorder In 5 Patients

この研究の注釈:

In a series of five case studies, supplementation of chromium initially alongside medication (and later as monotherapy) led to remission in dysthymic symptoms, notably depression.


A Double-blind, Placebo-controlled, Exploratory Trial Of Chromium Picolinate In Atypical Depression: Effect On Carbohydrate Craving

この研究の注釈:

In adult outpatients with atypical depression given 600mcg chromium (as picolinate) daily over the course of eight weeks, supplementation failed to outperform placebo in the primary intention to treat (overall depressive symptoms as assessed by HAM-D) but when assessing the parameters associated with food intake and carbohydrate cravings chromium appeared to outperform placebo by reducing cravings and food consumption.

In persons with high baseline carbohydrate cravings, there was also an improvement in genital symptoms (ie. libido) relative to placebo.


Effectiveness Of Chromium In Atypical Depression: A Placebo-controlled Trial

この研究の注釈:

Supplementation of 600mcg chromium (as picolinate) for 8 weeks in a pilot study of persons with major atypical depression noted that the majority of persons randomized to chromium (70% of the 10 person sample) experienced benefits as assessed by the response rate, although benefits on HAM-D and SCL-90 trended to meet statistical significance yet failed to do so.

研究の資金源に関する問題点:

Supported by a grant from Nutrition 21, producers of chromium supplementation